BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26384600)

  • 1. Applications of Fluorodeoxyglucose PET/Computed Tomography in the Assessment and Prediction of Radiation Therapy-related Complications.
    Houshmand S; Boursi B; Salavati A; Simone CB; Alavi A
    PET Clin; 2015 Oct; 10(4):555-71. PubMed ID: 26384600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diffuse increased FDG uptake of the atrial myocardium in the PET-CT as a result of irradiation-induced afterload].
    Meissnitzer T; Hergan K; Meissnitzer MW
    Rofo; 2015 Jul; 187(7):593-4. PubMed ID: 25750120
    [No Abstract]   [Full Text] [Related]  

  • 3. FDG PET/CT in the management of colorectal and anal cancers.
    Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
    AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
    Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
    PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies.
    Pattison DA; Hofman MS
    PET Clin; 2015 Oct; 10(4):461-76. PubMed ID: 26384593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer.
    Ciarallo A; Marcus C; Taghipour M; Subramaniam RM
    PET Clin; 2015 Apr; 10(2):265-78. PubMed ID: 25829091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients.
    Hatzoglou V; Ulaner GA; Zhang Z; Beal K; Holodny AI; Young RJ
    Clin Imaging; 2013; 37(3):451-7. PubMed ID: 23068052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.
    Gauthé M; Richard-Molard M; Cacheux W; Michel P; Jouve JL; Mitry E; Alberini JL; Lièvre A;
    Dig Liver Dis; 2015 Jun; 47(6):443-54. PubMed ID: 25766918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung cancer.
    Akhurst T; MacManus M; Hicks RJ
    PET Clin; 2015 Apr; 10(2):147-58. PubMed ID: 25829084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors.
    Segtnan EA; Hess S; Grupe P; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):59-73. PubMed ID: 25455880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [¹⁸F]fluorodeoxyglucose PET/computed tomography in breast cancer and gynecologic cancers: a literature review.
    Hildebrandt MG; Kodahl AR; Teilmann-Jørgensen D; Mogensen O; Jensen PT
    PET Clin; 2015 Jan; 10(1):89-104. PubMed ID: 25455882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET and PET-CT in radiation treatment planning for lung cancer.
    Aristei C; Falcinelli L; Palumbo B; Tarducci R
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):571-84. PubMed ID: 20397922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.
    Brix G; Lechel U; Glatting G; Ziegler SI; Münzing W; Müller SP; Beyer T
    J Nucl Med; 2005 Apr; 46(4):608-13. PubMed ID: 15809483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best practices: consensus on performing positron emission tomography-computed tomography for radiation therapy planning and for therapy response assessment.
    Blodgett T
    Semin Ultrasound CT MR; 2010 Dec; 31(6):506-15. PubMed ID: 21147378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dose management in CT, SPECT/CT and PET/CT techniques.
    Mattsson S; Söderberg M
    Radiat Prot Dosimetry; 2011 Sep; 147(1-2):13-21. PubMed ID: 21725080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.